Avastin gains approval for another cancer type
The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.
The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.
Genentech’s Avastin, in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, is approved for the treatment of women with advanced (stage 3 or 4) ovarian cancer following initial surgical resection.
Related: Top 3 new cancer drugs
Avastin is now approved in the United States for 10 distinct uses across 6 different types of cancer. This indication represents Avastin’s fourth gynecologic oncology indication in 4 years, including advanced cervical cancer and 2 different forms of ovarian cancer.
Related: FDA approves first drug for breast cancer with BRCA gene
“This approval represents an important milestone as the first medicine, other than chemotherapy, for women with advanced ovarian cancer after their initial surgery,” said Melissa Aucoin, CEO of the National Ovarian Cancer Coalition (NOCC), in a Genentech statement. “Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States, and this approval underscores Genentech’s dedication to bringing new treatment options to women with gynecological cancers.”
The approval for Avastin for advanced ovarian cancer is based a Phase 3 trial, which found that women who received Avastin in combination with chemotherapy, and continued use of Avastin alone, had a median progression-free survival (PFS) of 18.2 months compared to 12 months in women who received chemotherapy alone. “This PFS benefit was achieved with a fixed-duration treatment (up to 22 cycles of Avastin total),” Genentech said.
Read more: Cancer drug prices rise despite Trump plan
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
